Pyxis Oncology Q3 EPS Estimate Reduced by Leerink Partnrs

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Equities researchers at Leerink Partnrs reduced their Q3 2024 earnings per share (EPS) estimates for Pyxis Oncology in a research note issued on Tuesday, October 15th. Leerink Partnrs analyst J. La. Rosa now anticipates that the company will post earnings of ($0.35) per share for the quarter, down from their prior estimate of ($0.28). The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.07) per share. Leerink Partnrs also issued estimates for Pyxis Oncology’s Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.07) EPS, FY2025 earnings at ($1.33) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($1.17) EPS and FY2028 earnings at ($1.07) EPS.

PYXS has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Friday, August 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Thursday, September 19th. Finally, Stifel Nicolaus initiated coverage on Pyxis Oncology in a report on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Pyxis Oncology presently has a consensus rating of “Buy” and a consensus price target of $9.00.

Pyxis Oncology Trading Up 16.1 %

Shares of PYXS stock opened at $3.75 on Friday. Pyxis Oncology has a 1 year low of $1.35 and a 1 year high of $6.85. The firm’s 50 day moving average is $3.54 and its 200-day moving average is $3.77. The firm has a market capitalization of $220.83 million, a price-to-earnings ratio of -2.76 and a beta of 1.27.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently added to or reduced their stakes in the stock. StemPoint Capital LP bought a new stake in shares of Pyxis Oncology in the 1st quarter valued at about $7,643,000. Ikarian Capital LLC bought a new stake in Pyxis Oncology in the first quarter valued at approximately $7,082,000. Vanguard Group Inc. raised its holdings in Pyxis Oncology by 7.3% in the first quarter. Vanguard Group Inc. now owns 1,401,425 shares of the company’s stock worth $5,970,000 after purchasing an additional 94,740 shares during the period. Millennium Management LLC boosted its position in shares of Pyxis Oncology by 125.3% during the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after purchasing an additional 743,499 shares in the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new position in shares of Pyxis Oncology in the 2nd quarter valued at $3,462,000. Institutional investors and hedge funds own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.